Parallel Advisors LLC Increases Stock Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Parallel Advisors LLC raised its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 399.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 72,790 shares of the company's stock after buying an additional 58,218 shares during the period. Parallel Advisors LLC's holdings in Dr. Reddy's Laboratories were worth $1,149,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of RDY. Robeco Institutional Asset Management B.V. lifted its holdings in Dr. Reddy's Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after buying an additional 9,373,412 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Dr. Reddy's Laboratories by 609.4% in the fourth quarter. Van ECK Associates Corp now owns 5,838 shares of the company's stock valued at $92,000 after purchasing an additional 5,015 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Dr. Reddy's Laboratories by 400.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company's stock valued at $8,373,000 after purchasing an additional 427,573 shares during the period. World Investment Advisors LLC acquired a new position in Dr. Reddy's Laboratories during the 3rd quarter worth $3,459,000. Finally, Crossmark Global Holdings Inc. increased its holdings in Dr. Reddy's Laboratories by 328.3% during the 4th quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company's stock worth $201,000 after purchasing an additional 9,781 shares during the period. 3.85% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on RDY shares. Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th. StockNews.com downgraded shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, December 6th.

Dr. Reddy's Laboratories Stock Up 0.0 %

NYSE:RDY traded up $0.01 during trading hours on Monday, hitting $13.72. The company's stock had a trading volume of 3,085,934 shares, compared to its average volume of 1,270,218. The stock has a market capitalization of $11.45 billion, a P/E ratio of 21.84 and a beta of 0.48. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The stock has a fifty day moving average of $13.66 and a 200-day moving average of $14.68. Dr. Reddy's Laboratories Limited has a 52-week low of $12.50 and a 52-week high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, equities analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.